Want to join the conversation?
$ZTS 2Q15 PR: Reported revenue of $1.2Bil, which increased 1% vs. 2Q14. Revenue reflected an operational increase of 11%, excluding impact of FX. The net loss was $37MM, or $0.07 per diluted share including $263MM in pre-tax charges related to the company’s previously announced comprehensive operational efficiency initiative.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.